C O N M E D Corp is a well-established medical technology company that specializes in the development and manufacturing of innovative products for surgical and non-surgical procedures. The company focuses on providing advanced solutions in areas such as orthopedic surgery, endoscopy, and pain management, aiming to enhance patient outcomes and improve healthcare efficiency. Through its commitment to research and development, Conmed creates a portfolio of instruments, devices, and technologies designed to assist healthcare professionals in delivering high-quality care. The company prioritizes collaboration with clinicians to identify unmet needs in the medical field, thereby driving innovation that addresses both current and future healthcare challenges. Read More
CONMED (NYSE:CNMD) reported second-quarter 2026 net sales of $343.5 million, up 0.3% on a reported basis but down 0.5% in constant currency. Organic sales, which exclude the company’s exited gastroenterology product offerings, rose 6% year over year and modestly exceeded management’s expectations.
Medical tech company CONMED (NYSE:CNMD) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, but sales were flat year on year at $343.5 million...
CONMED Corporation (NYSE: CNMD) today reported financial results for the second quarter ended June 30, 2026 and updated its financial guidance for the full year ending 2026.
Medical tech company CONMED (NYSE:CNMD) will be reporting results this Wednesday after market close. Here’s what investors should know. CONMED beat analysts’...
CONMED Corporation (NYSE: CNMD) today announced that its AirSeal® Robotic Solution is now indicated for use with Intuitive’s 8 mm hex cannulas used as part of the Intuitive da Vinci 5 platform (“dV5”). Alongside its existing indication for Intuitive 8 mm round cannulas, the AirSeal Robotic Solution now has an expanded indication for use across Intuitive’s portfolio of da Vinci X, da Vinci Xi, and da Vinci 5 robotic systems.
CONMED Corporation (NYSE: CNMD) today announced its participation in the Society of Robotic Surgery (SRS) 2026 Annual Meeting, which is being held July 23-26, 2026 in Fort Lauderdale, FL.
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ...
What Happened? Shares of medical tech company CONMED (NYSE:CNMD) jumped 9% in the afternoon session after reports revealed the company is exploring a potenti...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
What Happened? Shares of medical tech company CONMED (NYSE:CNMD) fell 4.9% in the afternoon session after BofA Securities downgraded the stock to Underperfor...
CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (“CFO”), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the surgical equipment & consumables - diversified stocks, including CONMED (NYSE:CNMD)...
CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (“Board”), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. In connection with these appointments, CONMED is increasing the size of its Board to include a total of nine directors.
CONMED’s first quarter results were shaped by the company’s strategic exit from its gastroenterology (GI) product lines, which reduced reported sales but all...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Medical tech company CONMED (NYSE:CNMD) reported Q1 CY2026 results exceeding the market’s revenue expectations, but sales fell by 1.3% year on year to $317 m...
